|
|||||
|
|
Proteomic profiling of urine: implications for lupus nephritis |
|
| Authors: | Najla Aljaberi Michael Bennett Hermine I Brunner |
| Institution: | 1. Divisions of Rheumatology, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA;2. Division of Nephrology &3. Hypertension, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA |
| Abstract: | Introduction: Lupus nephritis (LN) is a common and significant manifestation, affecting 60% of adults and 80% of children with systemic lupus erythematosus, with up to 30% of patients progressing to end stage renal disease. There remains an unmet need for non-invasive markers of disease activity, damage, and response to therapy. In addition, non-invasive biomarkers that predict therapeutic efficacy are needed to enable cost-effective clinical trials of novel agents. Areas covered: This review examines the methodological aspects of urinary proteomics, the role of proteome profiling in identifying promising urinary biomarkers in LN, and the translation of research findings into clinically useful tools in the management of LN. Expert opinion: Targeted and unbiased proteomics have identified several promising urinary biomarkers that predict LN activity, damage (chronicity), and response to therapy. In particular, a combination of biologically plausible urinary biomarkers termed as RAIL (Renal Activity Index for Lupus) has emerged as an excellent predictor of LN activity as well as response to therapy, being able to predict efficacy within 3 months of therapy. If validated in additional large prospective studies, the RAIL biomarkers will transform the care of patients with LN, allowing for a personalized and predictive approach and improved outcomes. |
| Keywords: | Lupus nephritis systemic lupus erythematosus biomarkers urine |